Clinically tested drugs for Alzheimer’s disease

Bibliography

• PERRY EK, GIBSON PH, BLESSED G,PERRY RH, TOMLINSON BE: Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue.' Neurolog. Sci. (1977) 34(2):247–265.
   Google Scholar
• •One of the first reports of a cholinergic deficit in the cortex in AD.
   Google Scholar
• WHITE P, HILEY CR, GOODHARDT MJ et al: Neocortical cholinergic neurons in elderly people. Lancet (1977) 1(8013):668–671.
   PubMed Web of Science ®Google Scholar
• •One of the first reports of a cholinergic deficit in the cortex in AD.
   Google Scholar
• VAN DYCK CH, NEWHOUSE P, FALK WE, MATTES JA: Extended-release physostigmine in Alzheimer's disease: a multicenter, double-blind, 12-week study with dose enrichment. Arch. Gen. Psychiatry (2000) 57(2):157–164.
   PubMed Web of Science ®Google Scholar
• COELHO F, BIRKS J: Physostigmine for Alzheimer's disease. Cochrane Database Syst. Rev (2001) (2):CD001499.
   Google Scholar
• THAL LJ, FERGUSON JM, MINTZER J, RASKIN A, TARGUM SD: A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology (1999) 52(6):1146–1152.
   PubMed Web of Science ®Google Scholar
• QIZILBASH N, BIRKS J, LOPEZ-ARRIETA J, LEWINGTON S, SZETO S: Tacrine for Alzheimer's disease. Cochrane Database Syst. Rev. (2000) (3):CD000202.
   Google Scholar
• ••A systematic evaluation of all publishedcontrolled studies on tacrine in AD.
   Google Scholar
• RASKIND MA, CYRUS PA, RUZICKA BB, GULANSKI BI: The effects of metrifonate on the cognitive, behavioral and functional performance of Alzheimer's disease patients.' Clin. Psychiatry (1999) 60(5):318–325.
   Google Scholar
• FARLOW MR, CYRUS PA, NADEL A, LAHIRI DW, BRASHEAR A, GALANSKI B: Metrifonate treatment of AD: influence of APOE genotype. Neurology (1999) 53(9):2010–2016.
   PubMed Web of Science ®Google Scholar
• •• GALANSKI B: Metrifonate treatment of AD: influence of APOE genotype. Neurology(1999) 53(9):2010–2016.
   Google Scholar
• DUBOIS B, MCKEITH I, ORGOGOZO JM, COLLINS 0, MEULIEN D: A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study. Intl. I Ger. Psychiatry (1999) 14(11):973–982.
   PubMed Web of Science ®Google Scholar
• FARLOW MR, CYRUS PA: Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials. Dem. Ger. Xog. Dis. (2000) 11(4):202–211.
   PubMed Web of Science ®Google Scholar
• MORRIS JC, CYRUS PA, ORAZEM J et al: Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology (1998) 50(5):1222–1230.
   PubMed Web of Science ®Google Scholar
• MOSS DE, BERLANGA P, HAGAN MM, SAND OVAL H, ISHIDA C: Methanesulfonyl fluoride (MSF): a double-blind, placebo-controlled study of safety and efficacy in the treatment of senile dementia of the Alzheimer type. Alz. Dis. Assoc. Dis. (1999) 13(1):20–25.
   PubMed Web of Science ®Google Scholar
• FARLOW M, ANAND R, MESSINA J Jr, HARTMAN R, VEACH J: A 52-week study of the efficacy of ribastigmine in patients with mild to moderately severe Alzheimer's disease. Eur. Neurol (2000) 44(4):236–241.
   PubMed Web of Science ®Google Scholar
• BIRKS JS, GRIMLEY EVANS J, IAKOVIDOU V, TSOLAKI M: Rivastigmine for Alzheimer's disease. Cochrane Database Syst. Rev (2000) (4):CD001191.
   Google Scholar
• ••A systematic evaluation of all publishedcontrolled studies on rivastigmine in AD.
   Google Scholar
• ROSLER M, ANAND R, CICIN-SAIN A et al.: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. Br. Med. 318(7184):633–638.
   Google Scholar
• FARLOW MR, HAKE A, MESSINA J, HARTMAN R, VEACH J, ANAND R: Response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Arch. Neural. (2001) 58(3):417–422.
   PubMed Web of Science ®Google Scholar
• ROSLER M, ANAND R, CICIN-SAIN A et al.: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. Br. Med. (1999) 318(7184):633–638.
   PubMed Web of Science ®Google Scholar
• POTKIN SG, ANAND R, FLEMING K et al. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Intl. .1. Neuropsychopharm. (2001) 4(3):223–230.
   Google Scholar
• •A study using PET imaging using 18-F-fluorodeoxyglucose (PET-FDG) to show increased hippocampal metabolism in responders.
   Google Scholar
• BIRKS JS, MELZER D, BEPPU H: Donepezil for mild and moderate Alzheimer's disease. Cochrane Database Syst. Rev (2000) (4):CD001190.
   Google Scholar
• ••A systematic evaluation of all publishedcontrolled studies on donepezil in AD.
   Google Scholar
• HOMMA A,TAKEDA M, IMAI Y et al: Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. Dem. Ger. Cog. Dis. (2000) 11(6):299–313.
   Google Scholar
• ROGERS SL, DOODY RS, PRATT RD, IENI JR: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur: Neuropsychophann. (2000) 10(3):195–203.
   PubMed Web of Science ®Google Scholar
• •A very long-term (up to 240 week) study.
   Google Scholar
• DOODY RS, DUNN JK, CLARK CM et al.: Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dem. Ger. Cog. Dis. (2001) 12(4):295–300.
   PubMed Web of Science ®Google Scholar
• TARIOT PN, CUMMINGS JL, KATZ JR et al.: A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Am. Ger. Soc. (2001) 49(12):1590–1599.
   PubMed Web of Science ®Google Scholar
• DOODY RS, GELDMACHER DS, GORDON B, PERDOMO CA, PRATT RD: Open-label, multicenter, Phase III extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease. Arch. Neurol (2001) 58(3):427–433.
   PubMed Web of Science ®Google Scholar
• FELDMAN H, GAUTHIER S, HECKER J, VELLAS B, SUBBIAH P, WHALEN E: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology (2001) 57(4):613–620.
   PubMed Web of Science ®Google Scholar
• BURNS A, ROSSOR M, HECKER J et al: The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dem. Ger. Cogn. Dis. (1999) 10(3):237–244.
   PubMed Web of Science ®Google Scholar
• MOHS RC, DOODY RS, MORRIS JC et al.: A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology (2001) 57(3):481–488.
   PubMed Web of Science ®Google Scholar
• OLIN J, SCHNEIDER L: Galantamine for Alzheimer's disease. Cochrane Database Syst. Rev (2002) (3):CD001747.
   Google Scholar
• •A meta-analysis of published trials of galantamine.
   Google Scholar
• RASKIND MA, PESKIND ER, WESSEL T, YUAN W: Galantamine in AG: A 6-month randomized, placebo-controlled trial with a 7-month extension. Neurology (2000) 54(12):2261–2268.
   PubMed Web of Science ®Google Scholar
• WILCOCK GK, LILIENFELD S, GAENS E: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomized controlled trial. Br. Med. (2000) 321(7274):1445–1449.
   PubMed Web of Science ®Google Scholar
• TARIOT PN, SOLOMON PR, MORRS JC, KERSHAW P, LILIENFELD S, DING C: A 5-month, randomized, placebo-controlled trial of galantamine in AG. Neurology (2000) 54(12):2269–2276.
   PubMed Web of Science ®Google Scholar
• WILKINSON D, MURRAY J: Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. Intl. .1. Ger: Psychiatry (2001) 16(9):852–857.
   Google Scholar
• ROCKWOOD K, MINTZER J, TRUYEN L, WESSEL T, WILKINSON D: Effects of a flexible galantamine dose in Alzheimer's disease: a randomized, controlled trial. Neurol Neurosurg. Psychiatry (2001) 71(5):589–595.
   PubMed Web of Science ®Google Scholar
• ERKINJUNTTI T, KURZ A, GAUTHIER S, BULLOCK R, LILIENFELD S, DAMARAKU CV: Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. Lancet (2002) 359(9314):1265–1266.
   PubMed Web of Science ®Google Scholar
• IMBIMBO BP: Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs (2001) 15(5):375–390.
   PubMed Web of Science ®Google Scholar
• IMBIMBO BP, TROETEL WM, MARTELLI P, LUCCHELLI F: A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer's disease. Dem. Ger. Cog. Dis. (2000) 11(1):17–24.
   PubMed Web of Science ®Google Scholar
• IMBIMBO BP, VERDELLI G, MARTELLI P, MARCHESINI D: Two-year treatment of Alzheimer's disease with eptastigmine. Dem. Ger. Cogn. Dis. (1999) 10(2):139–147.
   Google Scholar
• BLASS JP, CYRUS PA, BIEBER F, GULANSKI B: Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and tolerability of metrifonate in patients with probable Alzheimer's disease. A/z. Dis. Assoc. Dis. (2000) 24(1):39–45.
   Web of Science ®Google Scholar
• THAL LJ, CALVANI M, AMATO A, CARTA A: A 1-year controlled trial of acetyl-carnitine in early-onset AD. Neurology (2000) 55(6):805–810.
   PubMed Web of Science ®Google Scholar
• LOPEZ-ARRIETA JM, RODRIGUEZ JL, SANZ F: Efficacy and safety of nicotine in Alzheimer's disease patients. Cochrane Database Syst. Rev (2001) (2):CD001749.
   Google Scholar
• WHITE HK, LEVIN ED: Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology (1999) 143(2):158–165.
   PubMed Web of Science ®Google Scholar
• WIENRICH M, MEIER D, ENSINGER HA et al.: Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man. Life Sciences (2001) 68(22-23):2593–2600.
   PubMed Web of Science ®Google Scholar
• THAL LJ, FORREST M, LOFT H, MENGEL H: Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Neurology (2000) 54(2):421–426.
   PubMed Web of Science ®Google Scholar
• BODICK NC, OFFEN WW, SHANNON HE et al: The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer's disease. Alz. Dis. Assoc. Dis. (1997) 11\(Suppl. 4):516–522.
   Google Scholar
• NITSCH RM, DENG M, TENNIS M, SCHOENFELD D, GROWDONJH: The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol (2000) 48(6):913–918.
   PubMed Web of Science ®Google Scholar
• SCHWARZ RD, CALLAHAN MJ, COUGHENOUR 11 et al: Milameline (CI-979/RU35926): a muscarinic receptor agonist with cognition-activating properties: biochemical and in vivo characterization. Pharmacol Exp. Ther: (1999) 291(2):812–822.
   PubMed Web of Science ®Google Scholar
• LOUDON JM, BROMIDGE SM, BROWN F et al: SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors. Pharmacol Exp. Ther: (1997) 283(3):1059–1068.
   PubMed Web of Science ®Google Scholar
• ALVAREZ )(A, MOUZO R, PICHEL V et al.: Double-blind placebo-controlled study with citicolline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Meth. Find. Exp. Clin. Pharmacol (1999) 21(9):633–644.
   Google Scholar
• MCGEER PL, MCGEER EG, KAMO H, WONG K: Positron emission tomography and the possible origins of cytopathology in Alzheimer's disease. Progr: Neuro-Psychopharmacol Biol. Psychiatry (1986) 10(3-5):501–518.
   PubMed Web of Science ®Google Scholar
• FLICKER L, GRIMLEY EVANS G: Piracetam for dementia or cognitive impairment. Cochrane Database Syst. Rev (2001) (2):CD001011.
   Google Scholar
• GREEN RC, GOLDSTEIN FC, AUCHUS AP et al: Treatment trial of oxiracetam in Alzheimer's disease. Arch. Neurol (1992) 49(11):1135–1136.
   PubMed Web of Science ®Google Scholar
• FALSAPERLA A, MONICI PRETI PA, OLIANI C: Selegiline versus codracetam in patients with Alzheimer-type dementia. Clin. Ther. (1990) 12(5):376–384.
   PubMed Web of Science ®Google Scholar
• CLAUS JJ, LUDWIG C, MOHR E, GIUFFRA M, BLIN J, CHASE TN: Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam. Neurology(1991) 41(4):570–574.
   PubMed Web of Science ®Google Scholar
• LE BARS PL, KIESER M, ITIL KZ: A 26-week analysis of a double-blind, placebo-controlled trial of the gingko biloba extract egb 761 in dementia. Dem. Ger. Cog. Dis. (2000) 11(4):230–237.
   PubMed Web of Science ®Google Scholar
• VAN DONGEN MC, VAN ROSSUM E, KESSELS AG, SIELHORST HJ, KNIPS CHILD PG: The efficacy of gingko for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial." Am. Ger. Soc. (2000) 48(10):1181–1194.
   Google Scholar
• LE BARS PL, VELASCO FM, FERGUSON JM, DESSAIN EC, KIESER M, HOERR R: Influence of the severity of cognitive impairment on the effect of the Ginkgo biloba extract EGb 761 in Alzheimer's disease. Neuropsychobiology (2000) 45(1):19–26.
   Web of Science ®Google Scholar
• RUETHER E, HUSMANN R, KINZLER E et al.: A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease. Intl. Clin. Psychopharmacol (2001) 16(5):253–263.
   PubMed Web of Science ®Google Scholar
• BAE CY, CHO CY, CHO K et al: A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease. Arn. Ger. Soc. (2000) 48(12):1566–1571.
   PubMed Web of Science ®Google Scholar
• PANISSET M, GAUTHIER S, MOESSLER H, WINDISCH M: Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent. Neural Trans. (2002) 109(7-8):1089–1104.
   PubMed Web of Science ®Google Scholar
• CUTLER NR, SHROTRIYA RC, SRAMEK JJ et al.: The use of the Computerized Neuropsychological Test Battery (CNTB) in an efficacy and safety trial of BMY 21,502 in Alzheimer's disease. Ann. NY Acad. Sci. (1993) 695:332–336.
   PubMed Web of Science ®Google Scholar
• SCHENK D, BARBOUR R, DUNN W et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 400(6740):173–177.
   PubMed Web of Science ®Google Scholar
• ••The first report that immunisation with arnyloid-I3 diminishes arnyloid-I3 load.
   Google Scholar
• JANUS C, PEARSON J, MCLAURIN J et al.: A beta-peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease. Nature (2000) 408(6815):970–982.
   Web of Science ®Google Scholar
• MORGAN D, DIAMOND DM, GOTTSCHALL PE et al.: A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2000) 408(6815):982–985.
   PubMed Web of Science ®Google Scholar
• STEINBERG D: Companies halt first Alzheimer vaccine trial. Scientist (2002) 16:22.
   Web of Science ®Google Scholar
• •First word of trouble in the vaccination with arnyloid43 trials.
   Google Scholar
• WEISS R: Test of vaccine to fight Alzheimer's halted: Inflammation in the brains of 12 volunteers quashes optimism. San Francisco Chronicle (22 February, 2002):A–3.
   Google Scholar
• MCGEER PL, MCGEER EG: Is there a future for vaccination as a treatment for Alzheimer's disease? Neurobiol Aging(2003) 24(2):391–395.
   PubMed Web of Science ®Google Scholar
• GREENBERG SM, BACSKAL BJ, HYMAN BT: Alzheimer's disease's double-edged vaccine. Nat. Med. (2003).
   Google Scholar
• NICOLL JAR, WILKINSON D, HOLMES C, STEART P, MARKHAM H, WELLWE RO: Neuropathology of human Alzheimer's disease after immunization with amyloid-b-peptide: a case report. Nat. Med. (2003) 9:448–452.
   PubMed Web of Science ®Google Scholar
• •First post-mortem scientific report on a case immunised with arnyloid-13.
   Google Scholar
• GRUBECK-LOEBENSTEIN B, BLASKO I, MARX FK, TRIEB I: Immunization with beta-amyloid: could T-cell activation have a harmful effect? Trends Neurosci. (2000) 23(3):114.
   Google Scholar
• GLENNER GG, WONG CW: Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. (1984) 120(3):885–890.
   PubMed Web of Science ®Google Scholar
• ••First report of the characterisation ofarnyloid.
   Google Scholar
• AUSTEN BM, SIDERA C, LIU C, FREARS E: The role of intracellular cholesterol on the processing of the P-amyloid precursor protein. Num. Health Aging(2003) 7(1):31–36.
   PubMedGoogle Scholar
• FRIEDHOFF LT, CULLEN El, GEOGHAGEN NS, BUXBAUM JD: Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide. Intl. .1. Neuropsychopharmacol (2001) 4(2):127–130.
   Google Scholar
• SIMONS M, SCHWARZLER F, LUTJOHANN D et al: Treatment with simvastin on noncholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann. Neurol (2002) 52(3):346–350.
   PubMed Web of Science ®Google Scholar
• WEYER G, EUL A, MILDE K, WIERICH W, HERRMANN WM: Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo-controlled multi-center study. Phannacopsychiatry (2000) 33(3):89–97.
   PubMed Web of Science ®Google Scholar
• NEUROINFLAMMATION WORKING GROUP: Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 21(3):383–421.
   PubMed Web of Science ®Google Scholar
• •An excellent review of neuroinflarnrnation in AD.
   Google Scholar
• MCGEER PL, MCGEER EG: The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Rev (1995) 21(2):195–218.
   PubMed Web of Science ®Google Scholar
• BROE GA, GRAYSON DA, CREASEY HM et al. Anti-inflammatory drugs protect against Alzheimer's disease at low doses. Arch. Neurol (2000) 57(11):1586–1591.
   PubMed Web of Science ®Google Scholar
• MCGEER PL, SCHULZER M, MCGEER EG: Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies. Neurology (1996) 47(2):425–432.
   PubMed Web of Science ®Google Scholar
• STEWART WE KAWAS C, CORRADA M, METTER EJ: Risk of Alzheimer's disease and duration of NSAID use. Neurology (1997) 48(3):626–632.
   PubMed Web of Science ®Google Scholar
• •One of the first large scale studies on NSAIDs and the risk of AD.
   Google Scholar
• IN T' VELD BA, RUITENBERG A, HOFMAN A et al. Non-steroidal antiinflammatory drug use and risk of Alzheimer's disease. New Engl. I Med. (2001) 345(21):1515–1521.
   Google Scholar
• ZANDI PP, ANTHONY JC, HAYDEN KM, MEHTA K, MAYER L, BREITNER JC: Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology (2002) 59(6)880–886.
   Google Scholar
• WOLFSON C, PERRAULT A, MORIDE Y, ESDAILE JM, ABENHAIM L, MOMOLI F: A case-control analysis of nonsteroidal anti-inflammatory drugs and Alzheimer's dsease: are they protective? Neuroepidemiology (2002) 21(2):81–86.
   PubMed Web of Science ®Google Scholar
• WEGGEN S, ERIKSEN JL, DAS P et al: A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature (2001) 414(6860):212–216.
   PubMed Web of Science ®Google Scholar
• AISEN PS, DAVIS KL, BERG JD et al: A randomized controlled trial of prednisone in Alzheimer's disease. Neurology (2000) 54(3):588–593.
   PubMed Web of Science ®Google Scholar
• AISEN PS, SCHMEIDLERJ, PASINETTI GM: Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology(2002) 58(7):1050–1054.
   PubMed Web of Science ®Google Scholar
• SAINALI SM, INGRAM DM, TALWAKER S, GEIS GS: Results of a double-blind, placebo-controlled study of celecoxib for the progression of Alzheimer's disease. 6th International Stockholm-Springfield Symposium of Advances in Alzheimer Therapy Stockholm, Sweden (2000).
   Google Scholar
• VAN GOOL, WA, WEINSTEIN HC, SCHELTENS P, WALSTRA GJ, SCHELTENS PK: Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomized, double-blind, placebo-controlled study. Lancet (2001) 358(9280)436–437.
   Google Scholar
• HOSCHL C, HAJEK T: Hippocampal damage mediated by corticosteroids - a neuropsychiatric research challenge. Eur. Arch. Psychiatry Clin. Neurosci. (2001) 251\(Suppl. 2):1181–1188.
   Google Scholar
• YASOJIMA K, SCHWAB C, MCGEER EG, MCGEER PL: Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Mohr Res. (1999) 830(2):226–236.
   Google Scholar
• ROGERS J, KIRBY LC, HEMPELMAN SR et al.: Clinical trial of indomethacin in Alzheimer's disease.Neurology (1993) 43(8):1609–1611.
   PubMed Web of Science ®Google Scholar
• ••First clinical trial of an NSAID in AD.
   Google Scholar
• TABET N, FELDMAN H: Indomethacin for the treatment of Alzheimer's disease patients. Cochrane Database Syst. Rev (2002) (2):CD003673, 2002.
   Google Scholar
• SCHARF S, MANDER A, UGONI A, VAJDA F, CHRISTOPHIDIS N: A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology (1999) 53(1):197–201.
   PubMed Web of Science ®Google Scholar
• ARAI H, SUZUKI T, SASAKI H, HANAWA T, TORIIZUKA K, YAMADA H: A new interventional strategy for Alzheimer's disease by Japanese herbal medicine. Nippon Ronen Igakkai Zasshi (2000) 37(3):212–215.
   PubMedGoogle Scholar
• KLEGERIS A, WALKER DG, MCGEER PL: Toxicity of human THP-1 monocytic cells towards neuron-like cells is reduced by non-steroidal anti-inflammatory drugs (NSAIDs). Neuropharmacology (1999) 38(7):1017–1025.
   PubMed Web of Science ®Google Scholar
• WALLACE JL, PITTMAN QJ, CIRINO G: Nitric oxide-releasing NSAIDs: a novel class of GI-sparing anti-inflammatory drugs. Agents Actions (1995) (Suppl. 46):121–129.
   Google Scholar
• CABRERA-GOMEZ, GA, LOPEZ-SAURA P: Alpha interferon and Alzheimer's disease. Rev. Neurol (2000) 30(1):54–60.
   PubMed Web of Science ®Google Scholar
• KLEGERIS A, MCGEER PL: Cyclooxygenase and 5-lipoxygenase inhibitors protect against microglial neurotoxicity. Neurobiol Aging (2002) 23(5):789–796.
   Web of Science ®Google Scholar
• COLTON CA, GILBERT DI: Production of superoxide anions by a CNS macrophage, the microglia. FEBS Lett. (1987) 223(2):284–288.
   PubMed Web of Science ®Google Scholar
• KLEGERIS A, MCGEER PL: Rat brain microglia and peritoneal macrophages show similar responses to respiratory burst stimulants. Neuroimmunol (1994) 53(1):83–90.
   Google Scholar
• BUTTERFIELD DA, KANSKI J: Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech. Aging Dev. (2001) 122(9):945–962.
   PubMed Web of Science ®Google Scholar
• WILLIAMSON KS, GABBITA SP, MOU S et al.: The nitration product 5-nitro-gamma-tocopherol is increased in the Alzheimer brain. Nitric Oxide (2002) 6(2)221–227.
   Google Scholar
• WILCOCK GK, BIRKS J, WHITEHEAD A, EVANS SJ: The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials. Intl. j Ger. Psychiatry (2002) 17(2):175–183.
   PubMed Web of Science ®Google Scholar
• BIRKS J, FLICKER L: Selegoline for Alzheimer's disease. Cochrane Database Syst. Rev (2000) (2):CD000442.
   Google Scholar
• FILIP V, KOLIBAS E: Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Psychiatry Neurosci. (1999) 24(3):234–243.
   PubMed Web of Science ®Google Scholar
• ALAFUZOFF I, HELISALMI S, HEINONEN EH et al.: Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease. Eut: I Clin. Pharmacol (2000) 55(11-12):815–819.
   PubMed Web of Science ®Google Scholar
• TABET N, BIRKS J, GRIMLEY EVANS J: Vitamin E for Alzheimer's disease. Cochrane Database Syst. Rev (2000) (4):CD002854.
   Google Scholar
• ADAIR JC, KNOEFEL JE, MORGAN N: Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology (2001) 57(8):1515–1517.
   PubMed Web of Science ®Google Scholar
• SQUITTI R, ROSSINI PM, CASSETTA E et al.: d-Penicillamine reduces oxidative stress in Alzheimer's disease patients. Eur: Clin. Invest. (2002) 32(1):51–59.
   PubMed Web of Science ®Google Scholar
• TSAI GE, FALK WE, GUNTHER J, COYLE JT: Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. Am. I Psychiatry (1999) 156(3):467–468.
   PubMed Web of Science ®Google Scholar
• TREVES TA, KORCZYN AD: Denbufylline in dementia: a double-blind controlled study. Dem. Get: Cogn. Dis. (1999) 10(6):505–510.
   PubMed Web of Science ®Google Scholar
• ASTHANA S, CRAFT S, BAKER LD et al.: Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. Psychoendocrinology (1999) 24(6):657–677.
   PubMed Web of Science ®Google Scholar
• HENDERSON VW, PAGANINI-HILL A, MILLER BL et al.: Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology (2000) 54(2):295–301.
   PubMed Web of Science ®Google Scholar
• MULNARD RA, COTMAN CW, KAWAS C et al.: Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. JAMA (2000) 283(8):1007–1015.
   PubMed Web of Science ®Google Scholar
• WANG PN, LIAO SQ, LIU RS et al: Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology (2000) 54(11):2061–2066.
   PubMed Web of Science ®Google Scholar
• OLIN J, SCHNEIDER L, NOVIT A, LUCZAK S: Hydergine for dementia. Cochrane Database Syst. Rev (2001) (2):CD000359
   Google Scholar
• LOPEZ-ARRIETA JM, BIRKS J: Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst. Rev (2002) (3):CD000147.
   Google Scholar
• BREITNERJC, WELSH KA, HELMS MJ et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging (1995) 16(4):523–530.
   PubMed Web of Science ®Google Scholar
• CARLSON MC, TSCHANZ JT, NORTON MC, WELSH-BOHMER K, MARTIN BK, BREITNER JC: H2 histamine receptor blockade in the treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled trial of nizatidine. Alz. Dis. Assoc. Dis. (2002) 16(1):24–30.
   PubMed Web of Science ®Google Scholar
• DYSKEN M, KUSKOWSKI M, LOVES: Ondansetron in the treatment of cognitive decline in Alzheimer dementia. Am. J. Ger. Psychiatry (2002) 1O(2):212–215.
   Google Scholar
• RODRIGUEZ-MARTIN JL, QIAIBASH N, LOPEZ-ARRIETA JM: Thiamine for Alzheimer's disease. Cochrane Database Syst. Rev (2001) (2):CD001498.
   Google Scholar
• HARDY I, SELKOE DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 297(5580):353–356.
   PubMed Web of Science ®Google Scholar
• VEHMAS AK, KAWAS CH, STEWART WE TRONCOSO JC: Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol Aging (2003) 24(2):321–331.
   PubMed Web of Science ®Google Scholar